Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 6/20 | 0.47 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19985024 | 0.84 | SLC6A9 (0.43) | SLC6A9EIF4A3NR1H2NR1H3CA12 | |
| SCHEMBL22055741 | 0.78 | POLB (0.57) | SLC6A9POLBMEN1KMT2ANR1H2 | |
| SCHEMBL19971958 | 0.76 | MAPT (0.47) | MEN1KMT2A | |
| SCHEMBL1711050 | 0.75 | MEN1 (0.74) | POLBMEN1KMT2ASLC6A7CA12 | |
| SCHEMBL12698691 | 0.75 | CA1 (0.48) | CA1CA2CA9 | |
| SCHEMBL18436642 | 0.75 | MEN1 (0.55) | SLC6A9MEN1KMT2ANR1H2NR1H3 | |
| SCHEMBL7133590 | 0.72 | RIPK1 (0.54) | MEN1KMT2A | |
| SCHEMBL19971955 | 0.72 | P2RX7 (0.44) | SLC6A9EIF4A3POLBNR1H2NR1H3 | |
| SCHEMBL2707267 | 0.71 | SIGMAR1 (0.61) | NR1H2NR1H3 | |
| SCHEMBL19562172 | 0.70 | MEN1 (0.67) | POLBMEN1KMT2ASLC6A7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | SLC6A9 4318/4885EIF4A3 4688/4885POLB 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.